Illumina (NASDAQ:ILMN) Price Target Raised to $230.00 at JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its price objective hoisted by JPMorgan Chase & Co. from $220.00 to $230.00 in a research report released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the life sciences company’s stock.

Several other equities research analysts have also commented on ILMN. Leerink Partners boosted their price objective on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research report on Friday. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. TD Cowen boosted their price target on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Canaccord Genuity Group increased their price objective on Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $175.47.

Illumina Stock Up 0.0%

Shares of NASDAQ ILMN opened at $205.10 on Friday. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 38.26, a price-to-earnings-growth ratio of 3.03 and a beta of 1.47. The company’s 50-day simple moving average is $176.70 and its 200-day simple moving average is $147.24. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina has a 52-week low of $88.00 and a 52-week high of $205.93.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 30.54%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Illumina will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. HighPoint Advisor Group LLC boosted its stake in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares during the period. Elevation Wealth Partners LLC increased its position in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the last quarter. Meeder Advisory Services Inc. raised its stake in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank raised its stake in shares of Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.